Do sodium-glucose cotransporter-2 inhibitors impact pulmonary symptoms in heart failure patients? A systematic literature review

Background: Sodium-glucose cotransporter-2 (SGLT2) inhibitors have shown promise for reducing adverse cardiovascular events in patients with heart failure. Our study looked at the effects of SGLT2 inhibitor use on pulmonary outcomes in patients with all types of heart failure. With comorbidities such as pulmonary hypertension in patients with heart failure, we looked at the evidence of pulmonary function in patients with heart failure through echocardiogram. Our study seeks to determine the use of SGLT2 inhibitors to alleviate pulmonary comorbidities in heart failure patients.